Showing results (211-220 of 302) with videos related to

Sort By:
Pageof 31
Plos One|June 21, 2012
A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosisLuc Dupuis, Reinhard Dengler, Michael T Heneka, et al.
Journal of Leukocyte Biology|November 8, 2025
Enhancing Tyro3 signaling ameliorates IL-1β production through STAT1 in Alzheimer's disease modelsKishore Aravind Ravichandran, Frederic Brosseron, Róisín M McManus, et al.
Nature|January 3, 2018
Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer's diseaseCarmen Venegas, Sathish Kumar, Bernardo S Franklin, et al.
Cell Reports|September 22, 2021
Proteopathic tau primes and activates interleukin-1β via myeloid-cell-specific MyD88- and NLRP3-ASC-inflammasome pathwayShanya Jiang, Nicole M Maphis, Jessica Binder, et al.
Annals of Clinical and Translational Neurology|June 15, 2021
Multi-cohort profiling reveals elevated CSF levels of brain-enriched proteins in Alzheimer's diseaseSofia Bergström, Julia Remnestål, Jamil Yousef, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 16, 2018
Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease-Data from three memory clinic studiesXiaochen Hu, Charlotte E Teunissen, Annika Spottke, et al.
The Journal of Clinical Investigation|October 27, 2020
mTOR-dependent translation amplifies microglia priming in aging miceLily Keane, Ignazio Antignano, Sean-Patrick Riechers, et al.
The Lancet. Neurology|June 24, 2018
Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trialAlbert C Ludolph, Joachim Schuster, Johannes Dorst, et al.
Nature|November 22, 2019
NLRP3 inflammasome activation drives tau pathologyChristina Ising, Carmen Venegas, Shuangshuang Zhang, et al.
European Journal of Neurology|January 19, 2024
In-depth analysis of data from the RAS-ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosisJoachim Schuster, Jens Dreyhaupt, Karla Mönkemöller, et al.
Pageof 31